FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:711-712 September 4, 1997 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gianni, A. M.

To the Editor: The report by Gianni et al. (May 1 issue)¹ concludes that high-dose sequential therapy is superior to a regimen of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) in a selected group of patients with aggressive non-Hodgkin's lymphoma. This conclusion could potentially change the standard treatment in a large number of patients with diffuse large-cell lymphoma of the B-cell type who are younger than 60 years. I should like to raise two questions.

The first question concerns the number of deaths. The authors report that four patients (8 percent) had fatal toxic reactions to the high-dose sequential . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.